Cabozantinib for Metastatic Triple Negative BrCa
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Cabozantinib
Sponsor: Dana-Farber Cancer Institute